Business
Arbutus is a clinical-stage biopharmaceutical company focused on infectious disease, with imdusiran and AB-101 for chronic hepatitis B.
Arbutus improved revenue, losses, and cash burn, but remains loss-making with weak forensic screens.
The read at a glance✓ Audited against SEC data
- Business mix — HBV therapeutics and LNP intellectual propertyNote
- Revenue — Revenue +128.2% to $14.1MOK
- Profitability — Net loss narrowed to $33.5MOK
- Cash burn — Free cash flow improved to -$39.6MOK
- Balance sheet — Equity -21.4% to $76.6MWatch
- Insiders — 0 buys / 0 sellsNote
- Accounting — Altman-Z distress; EQ greyWatch
Where the revenue comes from
Fiscal 2025, as Arbutus Biopharma Corp reports it. History and quarterly detail are in the app.
- Collaborations and licenses$12.6M
- License$10.4M
- Non-cash royalty revenue$1.5M
Leadership changes
From Arbutus Biopharma Corp's own filings, the day they're filed.
- David Hastings · Chief Financial Officer · departureeff. 2025-04-02
- Karen Sims · Chief Medical Officer · departureeff. 2025-03-25
- Michael J. Sofia · Chief Scientific Officer · departureeff. 2024-12-31
Latest filings
- 8-K · Company announcement2026-08-21
- 8-K · Company announcement2026-08-12
- 10-Q · Quarterly report2026-08-12
- 8-K · Company announcement2026-07-16
- 8-K · Company announcement2026-05-27
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Arbutus Biopharma Corp, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.